Indication: For treatment of idiopathic or postencephalitic Parkinson's disease, dysfunctions associated with hyperprolactinemia and in the treatment of acromegaly
Pharmacology: Bromocriptine is an ergoline derivitave dopamine agonist that is used in the treatment of amenorrhea, female infertility, abnormal discharge of breast milk, hypogonadism, Parkinson's disease, and acromegaly. Bromocriptine produces its therapeutic effect in the treatment of Parkinson's disease, a clinical condition characterized by a progressive deficiency in dopamine synthesis in the substantia nigra, by directly stimulating the dopamine receptors in the corpus striatum.
Mechanism Of Action: Bromocriptine acts by directly stimulating the dopamine receptors in the corpus striatum.
Interactions:
DrugBank: Interactions for Bromocriptine
Interactions for Bromocriptine:
The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated,
but alcohol may potentiate the side effects of bromocriptine mesylate. Bromocriptine mesylate may interact with
dopamine antagonists, butyrophenones, and certain other agents. Compounds in these categories result in a decreased
efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide. Concomitant use of
bromocriptine mesylate with other ergot alkaloids is not recommended.
Chemical IUPAC Name: Not Available
Chemical Formula: C32H40BrN5O5
Half Life: 4-15 hours
Drug Type: Approved Drug
# Accession No: APRD00622
CAS Registry Number: 25614-03-3
Bromocriptine News (When available)
Q HAVE been diagnosed with cyclical mastalgia. What can I do?Jan 30, 2006 Your GP may prescribe hormones like bromocriptine or danazol but these may have severe side effects. Q WHAT is the best way to treat my child for diarrhoea? ... - Glasgow Daily Record,
Imatinib mesylate (Gleevec) may not be effective at treating ...Dec 21, 2005 News-Medical.net, Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs ...
Dishman to expand EM capacity to 7.2mtJan 12, 2006 Business Standard, Dishman Pharmaceuticals plans to increase installed capacity of its Eprosartan Mesylate (EM) plant from 6. MT to 7.2 MT per month to meet the future demand of ...
Oscient Pharmaceuticals Provides Preliminary Revenues for Fourth ...Jan 9, 2006 Genetic Engineering News, ...quarter revenues of approximately $9.2 million, with approximately $8 million in revenue from its lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, and ...
Bio-IT BriefsJan 12, 2006 Bio-IT World, ...pharmacokinetic profile and potential efficacy of IPI-504 in patients with gastrointestinal stromal tumors (GIST) resistant to Gleevec (imatinib mesylate). ...
Oscient Pharmaceuticals to Present at 24th Annual JPMorgan ...Jan 3, 2006 Genetic Engineering News, CEO, Steven Rauscher, will provide an overview of the Company as well as an update on the market performance of FACTIVE(R) (gemifloxacin mesylate) tablets, the ...
Infinity Initiates Phase I Clinical Trial of IPI-504 for Patients ...Jan 10, 2006 PR Newswire (press release), ...pharmacokinetic profile and potential efficacy of IPI-504 in patients with gastrointestinal stromal tumors (GIST) resistant to Gleevec(R) (imatinib mesylate). ...
Effectiveness of Gleevec® Plus Hydroxyurea for Treatment of ...Dec 22, 2005 Cancer Consultants (press release), ...from the University of Pittsburgh, Dulman, Germany, and Duke University have reported that the combination of Gleevec (imatinib mesylate) plus hydroxyurea ...
Vaccine for Chronic Myeloid Leukemia Active in Patients with ...Jan 5, 2006 Business Wire (press release), ...of positive interim data for a novel vaccine known as VAX100 for patients with persistent chronic myeloid leukemia (CML) while on imatinib mesylate (Gleevec(R ...
New Pharmaceutical Treatment Options in the ElderlyDec 14, 2005 Medscape (subscription) Gemifloxacin mesylate (Factive). Gemifloxacin mesylate, which is given daily (320 mg for 5 to 7 days), is a new fluoroquinolone ...
Drug questionable in some kidney cancersDec 22, 2005 United Press International The drug in question, imatinib mesylate, used to treat patients with gastrointestinal stromal cancers, is said not likely to be effective for patients with high ...
Vaccine Shows Promise Against Residual Chronic Myeloid LeukemiaDec 27, 2005 Cancer Consultants (press release), Use of a cancer vaccine after treatment with Gleevec® (imatinib mesylate) may reduce or eliminate residual leukemia in some patients with chronic myeloid ...
Investigational Drug Shows Promise in Gleevec®-Resistent CMLDec 29, 2005 Cancer Consultants (press release), AMN107 has produced treatment responses in some patients with chronic myeloid leukemia (CML) that does not respond to Gleevec® (imatinib mesylate), as well as ...
Treatment with Gleevec® Continues to Show Benefits in CMLDec 28, 2005 Cancer Consultants (press release), ...to updated study results presented at the 47th annual meeting of the American Society of Hematology (ASH), Gleevec® (imatinib mesylate) produces good long ...
Ramoplanin Demonstrates High Activity Against Wide Array of ...Dec 19, 2005 PharmaLive.com (press release), The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ...
Gleevec® plus Hydroxyurea Beneficial for Some Patients with ...Dec 20, 2005 Cancer Consultants (press release), ...to a recent article published in the Journal of Clinical Oncology, the treatment combination consisting of Gleevec (imatinib mesylate) plus hydroxyurea ...
Desatinib Promising for Patients with CML Who Do Not Respond to ...Dec 23, 2005 Cancer Consultants (press release), ...still in clinical trials, is an effective treatment option for patients with chronic myelogenous leukemia (CML) who do not respond to Gleevec (imatinib mesylate ...
Glivec Seeking to Become First Targeted Treatment for Adult ...Dec 13, 2005 PharmaLive.com (press release), December 13, 2005 – Novartis has submitted a marketing authorization application for Glivec® (imatinib) Known as Gleevec® (imatinib mesylate) tablets in ...
Restless Legs Syndrome Fact SheetDec 14, 2005 Community Dispatch (press release) Dopamine agonists such as pergolide mesylate, pramipexole, and ropinirole hydrochloride may be effective in some patients and are less likely to cause ...
